Patrys Limited (PAB), a clinical stage biopharmaceutical company, is pleased to advise that it has just been granted a U.S. patent for lead product PAT-SM6. PAT-SM6 is a natural human antibody that has shown promise as a potential treatment for multiple types of cancer including melanoma and multiple myeloma. In February 2012, the Company announced successful data from a Phase I clinical trial in patients with in-transit melanoma.
Currently, the Company is preparing to undertake a Phase I/IIa clinical trial using PAT-SM6 in patients with relapsed and multi- resistant multiple myeloma. It is planned that this trial will commence at the University of Würzburg in the second half of 2012. The patent granted by the U.S. Patent Office as US 8,124,080 contains claims that cover the PAT-SM6 antibody binding to low-density lipoprotein (LDL) and components of LDL which are believed to be involved in the mode of action for the product. This is the second U.S. patent that has been granted covering the PAT-SM6 product. Patrys’ patent applications covering PAT-SM6 offer protection through to at least 2024 with the possibility of an extension of term.
Dr Marie Roskrow, Patrys’ CEO said: “The success in the granting of this recent PAT-SM6 patent is an endorsement of the novelty of our products and reinforces the commercial value of Patrys’ pipeline.” “This patent is a key component of our intellectual property (IP) portfolio and provides long term market exclusivity for Patrys’ PAT-SM6 product for the treatment of cancer. This issued patent expands our global IP protection as we plan to take the product into a second clinical trial.”
Based in Melbourne, Australia, Patrys (PAB) a clinical stage company, is focused on the development of natural human antibody therapies for cancer.